CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 23, 2017--
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present data
from Part A and Part B of the MoveDMD trial of edasalonexent (CAT-1004)
in an oral presentation at the upcoming 2017 Parent Project Muscular
Dystrophy (PPMD) Annual Connect Conference to be held June 29 – July 2,
2017, in Chicago, IL, at the Chicago Marriott Downtown.
Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will
deliver a presentation titled “MoveDMD: Phase 2 Trial of Edasalonexent,
an NF-kB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular
Dystrophy” on Friday, June 30, 2017, from 4:30pm – 4:45pm CT.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is
an investigational oral small molecule that is being developed as a
potential disease-modifying therapy for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a
protein that is activated in DMD and drives inflammation and fibrosis,
muscle degeneration and suppresses muscle regeneration. We are currently
conducting the MoveDMD trial, a three-part clinical trial investigating
the safety and efficacy of edasalonexent in boys ages 4 – 7 affected
with DMD (any confirmed mutation). The third part of the trial, an
open-label extension with edasalonexent, is ongoing. The FDA has granted
orphan drug, fast track and rare pediatric disease designations and the
European Commission has granted orphan medicinal product designation to
edasalonexent for the treatment of DMD. For a summary of clinical
results reported to-date, please visit www.catabasis.com.
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted) linker
drug discovery platform enables us to engineer molecules that
simultaneously modulate multiple targets in a disease. We are applying
our SMART linker platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to develop
additional product candidates. For more information on the Company's
drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170623005022/en/
Source: Catabasis Pharmaceuticals, Inc.
Investor and Media Contact
Andrea Matthews, 617-349-1971